Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years by Yoji Shido, Yukihiro Matsuyama

“…Pazopanib is a multitargeted tyrosine kinase inhibitor that has been clinically available from November 2012 in Japan. …”
Get full text

A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia by Umberto Romeo, Gaspare Palaia, Paolo Junior Fantozzi, Gianluca Tenore, Daniela Bosco

“…Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a good quality of life. …”
Get full text

Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models by Pallavi Sontakke, Jenny Jaques, Edo Vellenga, Jan Jacob Schuringa

“…These models not only mimic CML but also have been instrumental in uncovering various fundamental mechanisms of CML disease progression and tyrosine kinase inhibitor (TKI) resistance. With the availability of iPSC technology, it has become feasible to derive, maintain, and expand CML subclones that are at least genetically identical to those in patients. …”
Get full text

First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor by Rebecca Ganzon, Wei Chen, Gabriel Tinoco

“…Avapritinib is a tyrosine kinase inhibitor (TKI) approved in 2020 for adults with unresectable or metastatic gastrointestinal (GI) stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) Exon 18 mutation, including D842V mutations. …”
Get full text

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma by Jeremy L. Ramdial, Luis E. Aguirre, Robert A. Ali, Ronan Swords, Mark Goodman

“…Transient cytopenias and bone marrow hypoplasia commonly occur during treatment of CML with TKIs (tyrosine kinase inhibitors). This is usually related to the eradication of CML clones that initially compose the majority of hematopoietic cells in the bone marrow at the time of diagnosis. …”
Get full text

A novel treatment strategy with hyperbaric oxygen of chronic osteomyelitis and pseudoarthrosis in a child with congenital hereditary sensory and autonomic neuropathy type 4 congeni... by Anders Kjellberg, Rebecca Gustafsson, Pavel Antonsson, Henrik Hedelin

“…Congenital insensitivity to pain with anhidrosis is caused by a mutation in the neurotrophic receptor tyrosine kinase 1 gene (NRTK1). The condition is characterized by multiple injuries, recurrent infections, and mental retardation. …”
Get full text

Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas by Ozden Oz, Asuman Argon, Tulu Ayata Kebat, Ozlem Ozdemir, Savas Yakan

“…Introduction and Aim: Pancreas Ductal Adenocarcinomas (PDACs) are among the leading causes of cancer-related death. Tyrosine kinase receptors (TKRs) are responsible for cell plasticity, chemoresistance, immunosuppression and metastasis potential. …”
Get full text

Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Tre... by Jacob W. Bruinius, Karl J. Dykema, Sabrina L. Noyes, Bin Tean Teh, Brian R. Lane

“…There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data supporting its use in ChRCC is much more limited. …”
Get full text

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells by Fumiya Ito, Wakiko Iwata, Yoshihiro Adachi, Hiromi Sesaki, Miho Iijima

“…Further analysis revealed that GRHL2 upregulates the receptor tyrosine kinase HER3, and that HER3 knockdown similarly decreases the IC50 for erlotinib. …”
Get full text

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms by Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B. Aragon-Ching

“…Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. …”
Get full text

Role of Thyroid Hormone in Neurodegenerative Disorders of Older People by Arshag D. Mooradian, Michael J. Haas

“…The effect of THRP on cell viability is not modulated by c-Abl tyrosine kinase. The causal relationship between specific biochemical perturbations in cerebral tissue and thyroid dysfunction remains to be elucidated.…”
Get full text

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives by Antonio Rossi, Ettore Mari

“… EGFR mutations are the first identified targetable driver alterations in advanced non-small cell lung cancer (NSCLC), for which specific epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been developed. …”
Get full text

In Vivo Detection of c-MET Expression in a Rat Hepatocarcinogenesis Model Using Molecularly Targeted Magnetic Resonance Imaging by Rheal A. Towner, Nataliya Smith, Yasvir A. Tesiram, Andrew Abbott, Debbie Saunders, Rebecca Blindauer, Oana Herlea, Robert Silasi-Mansat, Florea Lupu

“…The multifunctional growth factor scatter factor/hepatocyte growth factor and its tyrosine kinase receptor, c-MET, have been implicated in the genesis and malignant progression of numerous human malignancies, including hepatocellular carcinomas. …”
Get full text

Characterization of a pleomorphic rhabdomyosarcoma cell line by Sandra Stickler, Clemens Lang, Maximilian Rieche, Marie-Therese Eggerstorfer, Martin Hohenegger, Maximilian Hochmair, Gerhard Hamilton

“…Results of the novel functional BH1522 tests corroborate published tumor sequencing data that demonstrated alterations in receptor tyrosine kinase/MAPK, PI3K/AKT and mutated p53 as suspected drivers of malignant growth.…”
Get full text

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China by Hua Zhong, Jun Lu, Mengzhao Wang, Baohui Han

“…The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first tyrosine kinase inhibitor (TKI) targeting the ROS1 pathway, crizotinib is widely used as a first-line regimen for ROS1-rearranged NSCLC. …”

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma by Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini

“…After progression on first line chemotherapy, was administered neratinib, a pan‐Erb2 receptor tyrosine kinase inhibitor. Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. …”
Get full text

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges by Erica di Martino, Darren C. Tomlinson, Margaret A. Knowles

“…Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLCγ1, PI3K, and STATs. …”
Get full text

Inflammatory Signalings Involved in Airway and Pulmonary Diseases by I-Ta Lee, Chuen-Mao Yang

“…The time course and intensity of responses by resident and circulating cells may be regulated by various inflammatory signalings, including Src family kinases (SFKs), protein kinase C (PKC), growth factor tyrosine kinase receptors, nicotinamide adenine dinucleotide phosphate (NADPH)/reactive oxygen species (ROS), PI3K/Akt, MAPKs, nuclear factor-kappa B (NF-κB), activator protein-1 (AP-1), and other signaling molecules. …”
Get full text

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs by Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng

“…In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). …”
Get full text

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation by Håkon Reikvam, Jørn Skavland, Stein-Erik Gullaksen, Randi Hovland, Tobias Gedde-Dahl, Øystein Bruserud, Bjørn Tore Gjertsen

“…Allogeneic stem cell transplantation (allo-SCT) was considered the first-line treatment for CML, before the introduction of tyrosine kinase inhibitors (TKIs). However, patients are at risk for relapse years after transplantation. …”
Get full text